Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
25/09/2026
J&J’s guselkumab showed significant improvement in axial PsA (Ref)
Johnson & Johnson’s TREMFYA® (guselkumab; anti-IL-23) met its primary and major secondary endpoints in the Phase 4 STAR study in biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA).
Guselkumab significantly improved spinal pain and stiffness and reduced MRI assessed inflammation.
The safety profile was consistent with TREMFYA’s established profile in PsA, with no new safety signals identified.
FDA approved Lilly's baricitinib for sever AA in paediatric patients aged 12 and older (Ref)
The US FDA approved Eli Lilly’s Olumiant (baricitinib) to for the treatment of severe alopecia areata (AA) in pediatric patients aged 12 and older.
The approval was based on the Ph3 BRAVE-AA-PEDS study, in which 42% of patients on 4 mg achieved ≥80% scalp hair coverage at Week 36.
The pediatric safety profile was consistent with adult findings; the label retains boxed warnings for serious infections, malignancy, MACE and thrombosis.


